Pluristem Therapeutics (PSTI) Receives Regulatory Approval To Extend Its Phase II Study of PLX-PAD Cells In The Treatment Of Intermittent Claudication To South Korea
11/13/2013 10:02:44 AM
HAIFA, Israel, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the South Korean Ministry of Food and Drug Safety (MFDS), formerly the Korea Food & Drug Administration (KFDA), has approved Pluristem's Investigational New Drug (IND) Application to conduct a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD).
Help employers find you! Check out all the jobs and post your resume.
comments powered by